By Condition

What GLP-1s actually treat

GLP-1 medications started as diabetes and obesity drugs — but the evidence now spans sleep apnea, heart disease, PCOS, fatty liver and more. Each guide below explains the condition, weighs the real trial evidence, and points you to the telehealth providers that treat it.

Also explore peptide therapies and the best GLP-1 providers.

Weight & metabolic

Obesity

Evidence A

FDA-approved indication (Wegovy, Zepbound)

Chronic excess body fat that raises the risk of dozens of other conditions — the core FDA-approved indication for GLP-1 weight-loss medications.

Cardiometabolic

Type 2 Diabetes

Evidence A

FDA-approved indication (Ozempic, Mounjaro)

A condition of high blood sugar and insulin resistance where GLP-1 and GLP-1/GIP drugs both lower A1c and support weight loss.

Prediabetes

Evidence B

Off-label; strong prevention evidence

Blood sugar that is elevated but not yet diabetic — where weight loss (including with GLP-1s) can delay or prevent progression to type 2 diabetes.

Obstructive Sleep Apnea

Evidence A

FDA-approved indication (Zepbound)

Repeated airway collapse during sleep, closely tied to obesity — tirzepatide (Zepbound) is now FDA-approved to treat moderate-to-severe OSA in adults with obesity.

Metabolic Syndrome

Evidence B

Off-label; improves each component

A cluster of risk factors — belly fat, high blood pressure, blood sugar, and lipids — that GLP-1-driven weight loss can improve across the board.

Cardiovascular Disease Risk

Evidence A

FDA-approved risk-reduction indication (Wegovy)

GLP-1s now carry FDA-approved indications to cut the risk of major cardiovascular events in adults with obesity or diabetes and existing heart disease.

Hormonal

PCOS

Evidence B

Off-label; growing evidence

A common hormonal disorder tied to insulin resistance and weight gain, where GLP-1s are increasingly used off-label to improve metabolic and reproductive markers.

Organ health

Fatty Liver Disease (MASLD/MASH)

Evidence B

Off-label; active late-stage trials

Fat buildup in the liver driven by metabolic dysfunction, where GLP-1 and dual/triple agonists are showing strong results for liver fat and inflammation.